Retatrutide: Entry #3 of 100+

Retatrutide: the triple agonist that’s going triple platinum. Generating more buzz than arguably every other pep as I’m posting this (for good reason).

TL;DR: 39-amino-acid synthetic peptide with agonist activity at three receptors — GIP, GLP-1, and glucagon. Phase 2 reported ~24% mean weight loss at 48 weeks at the 12 mg dose — currently the highest weight loss number for any anti-obesity drug at any phase. Phase 3 (TRIUMPH program) is ongoing. Not FDA-approved. Not legally available outside the trial.

Quick facts

Aliases: LY3437943, GGG tri-agonist (the "GGG" = GIP / GLP-1 / Glucagon)

Origin: 39-aa synthetic peptide engineered by Lilly; agonist at three different receptors at carefully balanced potencies

Class: GIP / GLP-1 / glucagon triple agonist

Route: SC weekly injection

Half-life: ~6 days

Doses studied: 1-12 mg SC weekly in Phase 2

Regulatory status:

Not FDA-approved; investigational only

Phase 3 TRIUMPH program ongoing across obesity, T2D, and comorbidity populations

Not available through compounding pharmacies; "retatrutide" sold as a research chemical online has no chain-of-custody and may not be the actual molecule

Mechanism(s)

GLP-1R + GIP-R agonism: same dual incretin axis as tirzepatide — insulin secretion, satiety, gastric emptying, GIP-related amplification effect

Glucagon receptor agonism: the differentiator and the strategic risk. Glucagon at the hepatocyte promotes fat oxidation and raises resting energy expenditure — a metabolic lever the GLP-1 and dual-incretin classes don't pull

The balance act: glucagon also raises hepatic glucose output. The GLP-1 component has to be potent enough to suppress that hyperglycemia, otherwise the drug would worsen diabetes rather than treat it. Tri-agonist design is mostly the engineering challenge of tuning the three potencies so they don't fight each other

Net effect: receptor-mediated appetite suppression (from GLP-1 + GIP) stacked on top of metabolically-driven calorie burn (from glucagon)

Research highlights

Jastreboff AM et al. 2023 (NEJM, PMID 37366315): Phase 2 in obesity — 24.2% mean weight loss at 48 weeks at 12 mg, dose-response observed from 1-12 mg, with the curve still trending downward at trial end (no clear plateau yet)

Rosenstock J et al. 2023 (Lancet): Phase 2 in T2D — strong HbA1c reduction, weight loss in line with the obesity cohort, no unexpected hepatic safety signal

Caveat: no Phase 3 efficacy or outcomes data published yet; long-term safety in a tri-agonist class is genuinely unknown

TRIUMPH-1/-2/-3/-4: Phase 3 program in progress; readouts expected staggered through the next 1-2 years

Side effects (reported in Phase 2)

Nausea, vomiting, diarrhea (similar pattern to GLP-1 class, dose-dependent)

Small heart rate increase (likely glucagon-driven)

No unexpected hepatic toxicity in Phase 2 despite the glucagon agonism — the GLP-1 + GIP arms appear to compensate

Long-term safety class-undefined: no other tri-agonist has been chronically dosed in humans at scale

The interesting part mechanistically:

Conventional wisdom for half a century was that glucagon is the enemy in metabolic disease — it raises blood sugar, you want less of it, that's why insulin exists in the first place. Retatrutide's entire bet is that controlled, balanced glucagon agonism paired with strong incretin agonism unlocks a third weight-loss lever the rest of the field can't reach: liver-driven energy expenditure. Glucagon at the hepatocyte oxidizes fat and raises resting metabolic rate; the GLP-1 + GIP arms keep blood sugar from running away while you do it. If the bet works at scale, retatrutide isn't just "more weight loss than tirzepatide" — it's a different physiological mechanism stacked on top of the GLP-1 mechanism, and that's why the Phase 2 numbers are so far ahead of the dual agonist. The open question — what TRIUMPH has to answer — is what 2-3 years of simultaneous activation across three hormone systems does to the cardiovascular system, the liver, the kidneys, and the feedback loops that those hormones evolved to regulate. The weight loss is the easy part. The long-term safety is the bet.

Find more information about Retatrutide and potential interactions with other peptides here.